EANS-News: Sloning BioTechnology and Henkel to Co-Operate in Enzyme Development

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

companies/DEWB investment holding

Puchheim/Düsseldorf, 29 June 2009 (euro adhoc) - Multinational
consumer chemicals company Henkel will use Sloning BioTechnology´s
proprietary protein engineering platform in their Laundry and Home
Care enzyme development.

The two companies announced that a first project has been launched
involving SlonoMax mutant libraries as part of a development process
aiming at the functional optimisation of a specific enzyme.

Enzymes constitute an important ingredient in many modern household
chemicals; their constant improvement is crucial to Henkel. Directed
Evolution processes are used to optimise their properties. "In the
past, we would generate huge collections of genetic variants of
promising enzymes and screen them for desired features. With
Sloning´s technology, we obtain libraries that precisely follow our
design and contain all desired mutants. We expect to considerably
increase our success rate and shorten development time", says
Karl-Heinz Maurer, Director Research and Development of Henkel´s
Laundry and Home Care division.

Sloning´s CEO Heinz Schwer explains: "Our genetic engineering
platform allows to introduce selected alternative codons, leading to
only those mutations the scientist actually wanted. This gives
researchers additional freedom in setting up their experiments. We
are happy to count Henkel among our customers. This underscores the
added value SlonoMax libraries provide to any directed evolution
process."

About Sloning Sloning BioTechnology GmbH specializes in the
production of highly diverse and precisely engineered gene libraries.
Sloning´s superior genetic libraries are essential in screening for
new and improved therapeutic or industrial proteins. At the heart is
its core technology, Slonomics®, a patented genetic engineering
platform using sets of double stranded DNA triplets. Sloning is an
investment holding of the listed venture capital company Deutsche
Effecten- und Wechsel-Beteiligungsgesellschaft AG (DEWB).

About Henkel Headquartered in Düsseldorf / Germany, Henkel KGaA has
about 55,000 employees worldwide and counts among the most
internationally aligned German-based companies in the global
marketplace. People in approximately 125 countries around the world
trust in brands and technologies from Henkel.

CONTACT:
Sloning Headquarter
Dr. Heinz Schwer, CEO
+49 89 80 90 95 - 0
h.schwer@sloning.com

or

Sloning North America
Garry Merry, Business Development
1 510-287-6600
g.merry@sloning.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Deutsche Effecten- und Wechsel-Beteiligungsges. AG (DEWB)
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Marco Scheidler

DEWB AG

Tel.: +49 (0) 3641 573-3600

E-Mail: marco.scheidler@dewb-vc.com

Branche: Financial & Business Services
ISIN: DE0008041005
WKN: 804100
Index: CDAX, Classic All Share, Prime All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Stuttgart / free trade
München / free trade